LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LONDON WALLET
  • Home
  • Investing
  • Business Finance
  • Markets
  • Industries
  • Opinion
  • UK
  • Real Estate
  • Crypto
No Result
View All Result
LondonWallet
No Result
View All Result

Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%

Robert Frost by Robert Frost
August 8, 2023
in Industries
Novo Nordisk shares pop after key trial data shows Wegovy cuts risk of heart attack or stroke by 20%
74
SHARES
1.2k
VIEWS
Share on FacebookShare on Twitter


Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy.

Stefan Trumpf | Picture Alliance | Getty Images

Shares of Danish drugmaker Novo Nordisk soared Tuesday, after late-stage trial data showed that its obesity drug Wegovy reduced the risk of major cardiovascular events such as heart attacks or strokes by 20%, compared with a placebo.

The results of the closely watched “SELECT” trial, which exceeded expectations, were seen as a major boost for the company’s hopes of moving beyond Wegovy’s image as a “vanity drug.”

Shares of Novo Nordisk ended the session up over 17%.

The double-blind trial began almost five years ago and involved more than 17,600 adults with established cardiovascular disease who were overweight or suffered from obesity, but had no prior history of diabetes.

The headline results show that the weekly injection of semaglutide 2.4 mg achieved its primary objection of reducing the risk of cardiovascular events, such as heart attacks or strokes, by 20% compared with a placebo. Wegovy contains 2.4 mg of semaglutide.

CNBC Health & Science

Read CNBC’s latest health coverage:

Investors and analysts had told Reuters that a risk reduction of between 15% and 17% would be interpreted as a positive result for the blockbuster weight loss drug.

Martin Holst Lange, executive vice president for development at Novo Nordisk, said that the results showed that the company’s obesity drug “has the potential to change how obesity is regarded and treated.”

“People living with obesity have an increased risk of cardiovascular disease but to date, there are no approved weight management medications proven to deliver effective weight management while also reducing the risk of heart attack, stroke or cardiovascular death,” Holst Lange said in a statement.

“Therefore, we are very excited about the results from SELECT showing that semaglutide 2.4 mg reduces the risk of cardiovascular events.”

The company said it expects to file for regulatory approvals of a label indication expansion for Wegovy in the U.S. and European Union this year.

Emily Field, head of European pharmaceuticals equity research at Barclays, told CNBC last month that the results of Novo Nordisk’s SELECT trial amounted to an important litmus test for the health industry.

In the event that the drug was found to have wider-reaching applications, including cardiovascular benefits, Field said that it was more likely that it could be adopted under mainstream health-care policies.

Public health services “don’t want to pay for it, if it won’t tackle underlying health conditions,” she said.

The detailed results from the SELECT trial will be presented at a scientific conference later in the year, Novo Nordisk said, without fully disclosing the timeline.

— CNBC’s Karen Gilchrist contributed to this report.



Source link

You might also like

Iraq pledges to end $4 billion gas imports from Iran by 2028 as it races to diversify beyond oil

Ford slashes F-150 Lightning prices by up to $4,000 and bumps up the range

US, Europe, and China drive global EV boom to record highs

Share30Tweet19
Previous Post

Coinbase begins $150M debt buyback at 36% discount

Next Post

Here’s what is behind the stock market’s selloff and what we’re doing about it

Robert Frost

Robert Frost

Jutawantoto Jutawantoto Jutawantoto Jutawantoto Berita Terbaru Hari

Recommended For You

Iraq pledges to end  billion gas imports from Iran by 2028 as it races to diversify beyond oil
Industries

Iraq pledges to end $4 billion gas imports from Iran by 2028 as it races to diversify beyond oil

October 15, 2025
Ford slashes F-150 Lightning prices by up to ,000 and bumps up the range
Industries

Ford slashes F-150 Lightning prices by up to $4,000 and bumps up the range

October 15, 2025
US, Europe, and China drive global EV boom to record highs
Industries

US, Europe, and China drive global EV boom to record highs

October 15, 2025
First-ever Jeep extended range EV, Mazda gets in the price war, and antique hybrids
Industries

First-ever Jeep extended range EV, Mazda gets in the price war, and antique hybrids

October 14, 2025
Next Post
Here’s what is behind the stock market’s selloff and what we’re doing about it

Here's what is behind the stock market's selloff and what we're doing about it

Related News

Banks are in limbo without a crucial lifeline. Here’s where cracks may appear next

Banks are in limbo without a crucial lifeline. Here’s where cracks may appear next

March 19, 2024
Strongest Q1 for BTR investment since 2022, says Savills – London Wallet

Strongest Q1 for BTR investment since 2022, says Savills – London Wallet

May 1, 2025
Bitcoin trader says it's still 'too early' to call BTC price bottom

Bitcoin trader says it's still 'too early' to call BTC price bottom

September 17, 2024

Browse by Category

  • Business Finance
  • Crypto
  • Industries
  • Investing
  • Markets
  • Opinion
  • Real Estate
  • UK

London Wallet

Read latest news about finance, business and investing

  • Contact
  • Privacy Policy
  • Terms & Conditions

© 2025 London Wallet - All Rights Reserved!

No Result
View All Result
  • Checkout
  • Contact
  • Home
  • Login/Register
  • My account
  • Privacy Policy
  • Terms and Conditions

© 2025 London Wallet - All Rights Reserved!

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?